Entities / Person
Hengrui.
Republic of China person CBDB = 91660
- Reports this week
- 0
- Active events
- 0
- Connections
- 11
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Hengrui Pharma is developing obesity treatments, with Su Zhang leading non-oncology clinical development at the company.Some support1 report
-
Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Hengrui this week
News at the entities that move Hengrui most-
Bristol-Myers Squibb TransactionalBMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Moves Hengrui
-
FDA Shared contextWaters Corporation and LabCorp are partnering to expand access to FDA-approved HPV testing options.Moves Hengrui
Connections
The 4 strongest of 11, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bristol-Myers Squibb Transactional
The relationship is characterized by the announcement and execution of significant business deals concerning drug program development.
-
Su Zhang Structural
Su Zhang holds the role of leading Non-Oncology Clinical Development at Hengrui Pharma.
-
Scott Wasserman Operational
Both individuals are involved in the competitive development of obesity treatments.
-
FDA Shared context
The entities are noted as operating within the context of U.S. and European drugmakers.